The adenosine, generated by the ectonucleotidases CD39 and CD73, has been recently proposed as a novel target since it plays a key role in the inhibition of anti-tumor response through the activation of adenosine receptor (A2AR) expressed on effectors cells [68,69]. The gene discussed is ENTPD1; the disease is neoplasm.